Fig. 1The cumulative incidence of diabetic complication in middle-age-onset and elderly-onset diabetes. (A) Cumulative incidence (%) of coronary revascularization in elderly-onset diabetes. (B) Cumulative incidence (%) of coronary revascularization in middle-age-onset diabetes. (C) Cumulative incidence (%) of retinopathy in elderly-onset diabetes. (D) Cumulative incidence (%) of retinopathy in middle-age-onset diabetes.
Table 1Clinical Characteristics of the Study Subjects
![enm-31-416-i001.jpg]()
Characteristic |
Value |
No. of patients |
289 |
Age, yr |
83.2±2.9 |
Sex, male/female |
141/148 (48.8/51.2) |
Body mass index, kg/m2
|
23.6±3.1 |
Duration of diabetes, yr |
14.3±10.4 |
Systolic blood pressure, mm Hg |
125.4±16.6 |
Diastolic blood pressure, mm Hg |
71.6±11.6 |
Hypertension |
217 (75.1) |
Dyslipidemia |
104 (36.0) |
Coronary revascularization |
65 (22.5) |
Cerebral infarction |
49 (17.0) |
Cancer |
38 (13.1) |
Blood urea nitrogen, mg/dL |
18.4±9.0 |
Creatinine, mg/dL |
1.1±0.5 |
GFR, mL/min |
64.3±24.6 |
Fasting blood glucose, mg/dL |
130.0±39.3 |
Postprandial blood glucose, mg/dL |
208.0±76.9 |
Glycated hemoglobin, % |
7.4±1.6 |
Hemoglobin, g/dL |
11.8±1.7 |
Total cholesterol, mg/dL |
154.1±33.9 |
Triglycerides, mg/dL |
128.3±58.2 |
HDL-C, mg/dL |
39.5±13.0 |
LDL-C, mg/dL |
87.3±28.2 |
Diabetic retinopathy |
97/172 (56.4) |
Microalbuminuria |
97/263 (36.9) |
Overt proteinuria |
43/263 (16.3) |
GFR <60 mL/min |
155/270 (57.4) |
Table 2Demographic and General Clinical Characteristics of Elderly-Onset and Middle-Age-Onset Type 2 Diabetes Patients
![enm-31-416-i002.jpg]()
Characteristic |
Elderly-onset diabetes |
Middle-age-onset diabetes |
P value |
Number |
199 (68.9) |
90 (31.1) |
|
Age, yr |
83.4±3.0 |
82.9±2.6 |
0.135 |
Mean age at diagnosis, yr |
74.6±6.1 |
56.0±6.8 |
<0.001 |
Sex, male/female |
97/102 |
44/46 |
0.982 |
Duration, yr |
8.8±5.8 |
26.9±6.9 |
<0.001 |
BMI, kg/m2
|
23.6±3.0 |
23.5±3.0 |
0.710 |
SBP, mm Hg |
124.8±16.3 |
126.4±17.1 |
0.463 |
DBP, mm Hg |
71.5±12.1 |
71.9±10.5 |
0.756 |
Hypertension |
150 (75.4) |
67 (74.4) |
0.865 |
Dyslipidemia |
71 (35.7) |
33 (36.7) |
0.944 |
Coronary revascularization |
45 (22.6) |
20 (22.2) |
0.890 |
Cerebral infarction |
33 (15.6) |
16 (17.8) |
0.785 |
Diabetic retinopathy (n=172) |
49/116 (42.2) |
48/56 (85.7) |
<0.001 |
Cancer |
26 (13.1) |
12 (13.3) |
0.852 |
Table 3Clinical Characteristics and Medication Histories of Elderly-Onset and Middle-Age-Onset Type 2 Diabetes Patients
![enm-31-416-i003.jpg]()
Characteristic |
Elderly onset diabetes (n=199) |
Middle-age-onset diabetes (n=90) |
P value |
Blood urea nitrogen, mg/dL |
17.3±6.2 |
21.0±13.1 |
0.018 |
Creatinine, mg/dL |
1.1±0.4 |
1.2±0.7 |
0.035 |
GFR, mL/min |
65.2±23.0 |
62.3±27.8 |
0.388 |
Fasting blood glucose, mg/dL |
128.1±39.0 |
135.3±40.0 |
0.250 |
Postprandial blood glucose, mmol/L |
196.3±68.0 |
233.0±88.5 |
0.002 |
Glycated hemoglobin, % |
7.3±1.5 |
7.8±1.6 |
0.005 |
Hemoglobin, g/dL |
12.0±1.7 |
11.5±1.6 |
0.027 |
Total cholesterol, mg/dL |
155.8±35.8 |
150.6±29.0 |
0.217 |
Triglycerides, mg/dL |
130.9±60.2 |
122.9±53.8 |
0.317 |
HDL-C, mg/dL |
39.3±12.0 |
40.0±15.1 |
0.705 |
LDL-C, mg/dL |
88.7±30.6 |
84.3±22.3 |
0.207 |
uACR |
154.7±335.3 |
220.0±503.9 |
0.235 |
Microalbuminuria (n=263) |
56/177 (31.6) |
42/86 (48.8) |
0.007 |
Overt proteinuria (n=263) |
27/117 (23.1) |
16/146 (11.0) |
0.491 |
GFR <60 mL/min |
94 (47.2) |
49 (54.4) |
0.256 |
Lifestyle change only |
17 (8.5) |
0 |
0.004 |
Sulfonylurea/glinide |
147 (73.9) |
59 (65.6) |
0.013 |
Metformin |
76 (38.2) |
43 (47.8) |
0.100 |
DPP4 inhibitor |
86 (43.2) |
44 (48.9) |
0.389 |
α-Glucosidase inhibitor |
8 (4.0) |
7 (1.1) |
0.189 |
Thiazolidinedione |
3 (1.5) |
1 (1.1) |
0.790 |
No. of OHAs |
|
|
0.741 |
1 |
55 (27.6) |
25 (27.8) |
2 |
85 (42.7) |
34 (37.8) |
≥3 |
31 (15.6) |
18 (20.0) |
Insulin use |
15 (7.5) |
23 (25.6) |
<0.001 |
ARB or ACE inhibitor |
125 (62.8) |
62 (68.9) |
0.250 |
Statins |
71 (35.7) |
35 (38.9) |
0.573 |
Aspirin |
85 (42.7) |
33 (36.7) |
0.334 |
Table 4Multiple Logistic Regression Analysis with Stepwise Selection Method Using Five Biologically Important Variables as Independent Variables, and the Development of Diabetic Retinopathy as the Dependent Variable
![enm-31-416-i004.jpg]()
Independent variable |
Partial regression coefficient |
Standard error |
Odds ratio (β) |
95% CI |
P value |
Duration of diabetes, yr |
0.139 |
0.024 |
1.149 |
1.096–1.204 |
<0.001 |
Table 5Multiple Logistic Regression Analysis with Stepwise Selection Method Using Six Biologically Important Variables as Independent Variables, and the Development of Diabetic Nephropathy as the Dependent Variable
![enm-31-416-i005.jpg]()
Independent variable |
Partial regression coefficient |
Standard error |
Odds ratio (β) |
95% CI |
P value |
GFR |
–0.024 |
0.006 |
0.976 |
0.965–0.987 |
<0.001 |
Duration of diabetes, yr |
0.051 |
0.014 |
1.053 |
1.025–1.081 |
<0.001 |
Table 6Multiple Logistic Regression Analysis with Stepwise Selection Method Using Six Biologically Important Variables as Independent Variables, and the Development of Coronary Revascularization as the Dependent Variable
![enm-31-416-i006.jpg]()
Independent variable |
Partial regression coefficient |
Standard error |
Odds ratio (β) |
95% CI |
P value |
GFR |
–0.015 |
0.006 |
0.985 |
0.973–0.997 |
0.017 |
Table 7Clinical Characteristics of Elderly-Onset Diabetes according to the Duration of Diabetes
![enm-31-416-i007.jpg]()
Characteristic |
Duration of diabetes, yr |
P value |
<5 |
5–15 |
≥15 |
No. of patients |
59 |
98 |
42 |
|
Age, yr |
83.2±2.7 |
82.9±2.8 |
85.0±3.3 |
0.011 |
Sex, male/female |
32/27 |
47/51 |
18/24 |
0.253 |
Body mass index, kg/m2
|
24.3±3.4 |
23.3±2.9 |
23.3±2.8 |
0.070 |
Duration of diabetes, yr |
2.1±1.5 |
9.2±2.7 |
17.2±2.1 |
<0.001 |
SBP, mm Hg |
126.0±14.9 |
123.0±16.2 |
127.7±18.3 |
0.746 |
DBP, mm Hg |
72.2±11.9 |
70.3±12.7 |
73.4±11.0 |
0.732 |
Hypertension |
44 (74.6) |
71 (72.4) |
35 (83.3) |
0.376 |
Dyslipidemia |
20 (33.9) |
36 (36.7) |
15 (35.7) |
0.805 |
Coronary revascularization |
15 (25.4) |
18 (18.4) |
12 (28.6) |
0.828 |
Cerebral infarction |
10 (16.9) |
17 (17.3) |
6 (14.3) |
0.719 |
Cancer |
10 (16.9) |
15 (10.2) |
1 (2.4) |
0.040 |
Fasting blood glucose, mg/dL |
128.1±47.9 |
125.4±34.1 |
134.7±36.7 |
0.976 |
Postprandial blood glucose, mg/dL |
179.7±66.1 |
196.1±69.7 |
216.1±62.7 |
0.976 |
Glycated hemoglobin, % |
7.4±1.7 |
7.1±1.5 |
7.3±1.3 |
0.640 |
LDL-C, mg/dL |
98.3±35.6 |
85.5±27.3 |
81.9±27.0 |
0.238 |
Blood urea nitrogen, mg/dL |
17.3±6.1 |
17.3±6.4 |
17.7±5.8 |
0.519 |
Creatinine, mg/dL |
1.0±0.3 |
1.1±0.4 |
1.1±0.4 |
0.034 |
GFR, mL/min |
71.6±22.5 |
63.0±21.5 |
61.3±25.8 |
0.018 |
Diabetic retinopathy (n=116) |
3/30 (10.0) |
32/64 (50.0) |
14/22 (63.6) |
<0.001 |
Microalbuminuria (n=177) |
13/55 (23.6) |
29/88 (33.0) |
14/34 (41.2) |
0.078 |
Overt proteinuria (n=177) |
3/55 (5.5) |
14/88 (15.9) |
10/34 (29.4) |
0.002 |
GFR <60 mL/min (n=180) |
15/55 (27.3) |
47/90 (52.2) |
26/35 (74.3) |
<0.001 |